GLP-1s are highly effective at controlling blood sugar and slowing down gastric processes, but they are also highly effective (so to speak) at bringing on side effects like constipation, nausea, and abdominal pain that, if untreated, will impact adherence and, in turn, short and long term results
Irritable Bowel Syndrome
On May 21, Lilly reported that its GIP/GLP-1/glucagon triple hormone receptor agonist retatrutide, at the 12 mg dose over 80 weeks, produced an average 28.7% absolute weight loss in adults with obesity or overweight plus at least one weight-related comorbidity
In OASIS 4, gastrointestinal effects affected around 74% of those on the Wegovy pill compared with 42% on placebo, led by nausea (roughly 47% vs 19%) and vomiting (about 31% vs 6%), with diarrhoea and constipation also common
Some users are prescribed this option when stronger or more consistent results are needed